Local biopharma Ascentage Pharma raises $150M for cancer drug pipeline – Washington Business Journal
Ascentage Pharma, a global biopharmaceutical company with a local hub in Maryland, has raised $150 million in Series C financing.
Is your biohealth company located in Maryland, DC or Virginia? Are you thinking of applying for a biohealth related SBIR grant? Does your technology qualify? Are you eligible? Should you apply to NIH? NSF? to other organizations?
Sign up now to learn more from one of BHI’s SBIR consultants. Office hours are scheduled next in Montgomery County August 8th and 15th. (There is no fee for this service. Depending upon your technology and stage in the business cycle, BHI may also prepay for experts to help you improve your SBIR and other non-dilutive funding applications. For more information, click here.)
Due to company graduations, co-working and individual office space is becoming available at the Montgomery County innovation centers located in Rockville and Germantown. Each location offers shared meeting and kitchenette/lunch room space, and affordable, flexible lease terms. Tenants in these facilities also have access to BHI Entrepreneurs-in-Residence analysts, and other professional staff for additional support. For more information, contact BHI.
RESI/Life Science Nation are hosting a day of partnering and networking at RESI/Life Science Nation’s inaugural First Coast Innovators Gathering. Biohealth incubators, accelerators, tech transfer offices, and research labs from the East Coast can promote their organizations and spinout companies to RESI’s audience investors and partners seeking to connect with the region’s earliest stage companies. Participating organizations also are able to offer their companies discounted attendance to day one. For more information, click here.
For the first time this fall, Life Science Nation (LSN) will have two days of competition as part of the RESI Healthtech Week (September 5-7, 2018). Day 1 will feature the First Coast Innovation Challenge, where the top 10 ranked companies of the First Coast tech hubs will present their technologies as a 10-minute pitch to a panel of early-stage investors. Day 2 features the traditional RESI Innovation Challenge, where the top 30 companies who apply are chosen to showcase a poster on the RESI Global Partnering Conference Exhibit Hall. First Coast Innovation Challenge is geared toward companies which have recently moved out of the lab and are ready to target grant, angel, and seed funding. The First Coast Innovation Challenge on Day 1 complements the RESI Global Innovation Challenge on Day 2, offering greater investor exposure to companies from the earliest stage to more established startups that are looking globally and seeking funding from institutional investors.
Apply by this Friday, July 27th to participate in First Coast Innovation Challenge.
GlaxoSmithKline is reportedly considering whether to split its business into a consumer health spin-off and standalone pharmaceutical and vaccines group.
U.S. Senator Tim Kaine (D-VA) today visited Vibrent Health, a Fairfax, Virginia-based health technology company for a tour of the company’s new office followed by a town hall session with Vibrent’s 140 employees.
“Studying and developing new technologies is critical to improving our health care system and expanding access to more Virginians. I’m looking forward to learning more about the work Vibrent Health is doing to modernize the industry as well as hearing from their employees on how the Senate can better support innovation in the health care space,” said Kaine.
Following an advisory panel recommendation on July 6, the US Food and Drug Administration has approved, under Priority Review, single-dose Krintafel (tafenoquine) for the radical cure (prevention of relapse) of Plasmodium vivax (P. vivax)malaria in patients aged 16 years and older who are receiving appropriate antimalarial therapy for acute P. vivax infection.
Venture capital investment in early-stage biotechnology and pharmaceutical startups is seeing exuberance that could be classed as “froth,” but it does not appear to be in bubble territory yet.
Gaithersburg biotech startup Neuraly has raised $36 million for its potential Alzheimer’s disease and Parkinson’s disease treatment, the company announced.